To include your compound in the COVID-19 Resource Center, submit it here.

NIH won’t use march-in to lower prices

NIH Director Francis Collins said at congressional hearing on Thursday that the agency will not use “march-in” rights over medical products patented by the

Read the full 247 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE